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NK cell from human embryonic stem cells and induced 
pluripotent stem cells are challenging improvements for 
NK cell-based immunotherapy. Transfer of several of these 
protocols to clinical-grade production of NK cells necessi-
tates adaptation of good manufacturing practice conditions, 
and the development of freezing conditions to establish NK 
cell stocks will require some effort and, however, should 
enhance the therapeutic options of NK cells in clinical 
medicine.
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LAK  Lymphokine-activated killer
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Abstract Natural killer (NK) cells have been used in 
several clinical trials as adaptive immunotherapy. The low 
numbers of these cells in peripheral blood mononuclear 
cells (PBMC) have resulted in various approaches to pref-
erentially expand primary NK cells from PBMC. While 
some clinical trials have used the addition of interleukin 2 
(IL-2) to co-stimulate the expansion of purified NK cells 
from allogeneic donors, recent studies have shown prom-
ising results in achieving in vitro expansion of NK cells 
to large numbers for adoptive immunotherapy. NK cell 
expansion requires multiple cell signals for survival, prolif-
eration and activation. Thus, expansion strategies have been 
focused either to substitute these factors using autologous 
feeder cells or to use genetically modified allogeneic feeder 
cells. Recent developments in the clinical use of genetically 
modified NK cell lines with chimeric antigen receptors, the 
development of expansion protocols for the clinical use of 
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NK  Natural killer
PBMC  Peripheral blood mononuclear cells
Introduction
Natural killer (NK) cells are potent effectors of the innate 
immune system and form the first line of defense against 
diseases, including malignancies. They are members of the 
innate lymphoid cell family and characterized in humans 
by expression of the phenotypic marker CD56 (neural cell 
adhesion molecule) in the absence of CD3 (T-cell co-recep-
tor) [1]. The NK cell cytotoxic attack is immediate, does not 
require prior antigen-priming and is instead orchestrated 
in a unique way by an array of receptors with activating or 
inhibitory functions. Important activating receptors include 
the C-type lectin-like receptors CD94/NKG2C and NKG2D 
and the natural cytotoxicity receptors (NCR) NKp30, 
NKp44 and NKp46, which recognize ligands on tumor cells 
or virally infected cells. NK cell inhibition is essentially 
mediated by interactions of the polymorphic inhibitory 
killer cell immunoglobulin-like receptors (KIRs) with their 
cognate human–leukocyte–antigen (HLA) ligands. These 
HLA-ligands are bound by KIR using simplified amino 
acid (AA) structures in the alpha-1 helix of the HLA mol-
ecule. HLA-ligands are subdivided into three major motifs, 
HLA-Group 1 or C1 (Ser77/Asn80), HLA-Group 2 or C2 
(Asn77/Lys80) and HLA-Bw4 (AA position 77–83) which 
bind predominantly to inhibitory KIR characterized by a 
long extracellular immunoglobulin domain(Table 1). Other 
NK cells inhibitory receptors specific for HLA class I mol-
ecules are CD94/NKG2A with the non-classical class I mol-
ecule HLA-E as ligand and the leukocyte Ig-like receptor-1 
binding to HLA-G1 [2, 3]. NK cell inhibition is essential to 
prevent their attacks on healthy ‘self’-tissue; on the other 
hand, it needs to be overcome in therapeutic application of 
NK cells against transformed cells. The discovery of donor-
derived alloreactive NK cells present in T-cell-depleted 
HLA haplo-identical grafts for hematopoietic stem cell 
transplantation (HSCT) was a milestone in the field of NK 
cell therapy [4, 5]. Such haplo-mismatched NK cells exerted 
potent anti-leukemia effects in the absence of graft-versus-
host disease (GvHD) [6]. Haplo-identical HSCT provides 
a valuable treatment option for high-risk leukemia patients 
and, however, remains afflicted with transplant-related 
morbidity and mortality [7, 8]. Severe infection risks after 
the intensive transplant conditioning regimens and GvHD 
caused by alloreactive T cells in the graft are major com-
plications. Novel developments to optimize this type of 
therapy are under way. An important approach is the focus 
on the generation of grafts with defined cell compositions to 
achieve potent graft-versus-leukemia (GvL) effects with low 
incidences of severe side effects.
Several studies showed that NK cell alloreactivity has 
a clinical benefit in overall survival and reduced relapse 
rates for patients after HSCT in HLA-identical settings [8–
10]. Patients with a ‘mismatch’ of KIR and HLA-ligands 
(‘receptor–ligand’ concept) in graft-versus-recipient direc-
tion showed reduced relapse rates underlining the GvL 
effect of allogeneic NK cells [8]. In contrast to the earlier 
clinical studies of NK cell mismatches based on solely 
HLA (KIR–ligand) typing of donor and recipient (‘ligand–
ligand’ concept), these studies included the typing of KIR 
receptors beside HLA genes of the donor (Fig. 1). This 
strategy allowed for the differential analysis of the ‘mis-
match’ effect comparing the ‘ligand–ligand’ versus the 
‘receptor–ligand’ concept. While the ‘ligand–ligand’ con-
cept is based on the differences of the HLA-pattern (e.g., 
HLA-C locus antigens) between recipients and donors, the 
‘receptor–ligand’ concept requires the typing of KIR genes 
in order to adjust the KIR expression in the donor and 
hence alloreactive NK cells in the stem cell graft. A com-
parative analysis based on identical clinical study cohorts 
of adult patients transplanted with matched unrelated 
donors has been performed by Leung, Handgretinger and 
co-workers showing that the selection of donors (grafts) 
should be based on the ‘receptor–ligand’ model [10]. This 
study and other underlined the importance to perform KIR 
gene typing of preferential donors in order to adjust the 
clinical risk [8–11]. Most of these studies have underlined 
the clinical relevance of the inhibitory NK cell receptors 
KIR2DL1, KIR2DL2/3 and KIR3DL1 interacting with the 
three HLA ligand motifs C1, C2 and Bw4, respectively.
Functions of activating KIR receptors on the outcome 
of HSCT are only recently being unveiled. Graft recipients 
from HLA-identical siblings had a reduced relapse rate, 
Table 1  Binding of selected inhibitory and activating KIRs to HLA-
ligands
a DL = inhibitory receptors with long extracellular domain
b DS = activating receptor with short extracellular domain
c Group 1 (C1): C*01, *03, *07, *08, *12:02, *12:03, *13, *14, 
*16:01, etc
d Group 2 (C2): C*02, *04, *05, *06, *07:07, *07:09, *12:04, *15, 
*16:02, *17, *18, etc
NK receptor HLA-epitope AA binding motif
KIR2DL2/3a HLA-C Group 1 (C1)c Ser77/Asn80 (α1 helix)
KIR2DL1 HLA-C Group 2 (C2)d Asn77/Lys80 (α1 helix)





KIR2DS1b HLA-C Group 2 (C2) Asn77/Lys80 (α1 helix)
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if donor genotypes contained the activating KIR recep-
tor genes KIR2DS1 and KIR2DS2 [12, 13]. Recipients of 
grafts from donors homozygous or heterozygous for the 
KIR group B haplotype, containing more than one activat-
ing KIR gene in comparison to KIR haplotype A, displayed 
better overall survival [14, 15]. This effect was even more 
pronounced if donors were homozygous for centromeric B 
gene motifs containing KIR2DS2 when compared to hap-
lotype A donors missing KIR2DS2 [14]. In addition, recent 
studies could demonstrate protective effects for telomeric 
activating KIR3DS1 and KIR2DS1 on transplant outcome. 
While patients receiving unrelated grafts from KIR2DS1 
donors had a reduced relapse rate, patients receiving grafts 
for KIR3DS1 donors were characterized by a lower risk of 
grade II–IV GvHD and mortality [16]. In the study of Ven-
strom et al, the effect of KIR2DS1 was mediated by grafts 
from donors with KIR2DS1 genes on a C1-positive HLA 
background (C1/C1 or C1/C2), while patients receiving 
grafts from donors with KIR2DS1 genes on a C2/C2 HLA 
background had significantly higher relapse rates [17].
In addition to donor KIR gene content, KIR allelic pol-
ymorphism has been shown to have an impact on recipi-
ent outcome after HSCT. KIRs that regulate NK cells are 
highly polymorphic and KIR alleles encode receptors that 
have stronger signaling function than others [18]. Bari and 
colleagues showed that patients who received a KIR2DL1-
R(245)-positive graft with HLA-C receptor–ligand mis-
match had the best survival and lowest risk of leukemia 
progression compared with those patients who received 
a KIR2DL1-C(245) homozygous graft [19]. Thus, KIR 
allelic subtyping of allogeneic NK could be beneficial 
for donor selection in the transplant setting as well as for 
immunotherapies optimizing GvL effects.
Recent publications point toward rapid immune recon-
stitution and sustained persistence of NK cells with high-
level surface expression of CD94/NKG2C in patients with 
cytomegalovirus (CMV)-reactivation post-HSCT [20]. A 
development of ‘memory’ NK cells in such patients has 
been postulated. A reduction in the risk of leukemia relapse 
within the first-year post-HSCT was found, however, no 
increase in overall survival [21]. Further investigations 
are necessary to identify the underlying mechanisms and 
to better estimate the extent of the therapeutic potential of 
NK cells in transplant settings involving CMV reactivation 
[22].
The therapeutic potential of NK cells has led to several 
approaches in immunotherapy that can be summarized 
under the following principles.
(1) Autologous NK cells can be activated and potentiated 
through systemic administration of cytokines like 
interleukin (IL)-2, IL-12, IL-15, IL-18, IL-21 and type 
I IFNs. Despite safe administration of ex vivo activated 
and expanded autologous NK cells using cytokines and 
the generation of PBMCs with enhanced cytotoxicity 
against NK-resistant targets, no clinical responses in 
cancer patients were seen [23, 24].
(2) Allogeneic NK cells in adoptive cell transfer have 
shown beneficial cytotoxic effects killing malignant 
cells/tumors based on the ‘KIR mismatch’ principle 
[25, 26]. This approach is highly effective in HLA 
haplo-identical transplantation settings, but requires a 
more detailed analysis of HLA and NK KIR gene pat-
tern if used in HSCT using HLA matched related or 
unrelated donors. Donor lymphocyte infusion (DLI) 
takes advantage of NK cell alloreactivity of cells that 
(a) KIR – HLA-ligand match 





















Recipient cell (C2 negativ) 
KIR2DL1 
Bw4+ 
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Fig. 1  Schematic view of NK cell KIR receptor inhibition by C1, C2 
and Bw4 ligands expressed by recipient tumor cells. a The patient 
expresses C1, C2 and Bw4 KIR ligands and KIR2DL1-, KIR2DL2/3- 
and KIR3DL1-positive donor NK cells are inhibited (KIR–HLA 
match, no KIR–ligand missing). b The patient expresses C1, and Bw4 
KIR ligands (C2 is missing), single-KIR2DL1+ donor NK cells are 
not inhibited and can take part in the graft-versus-tumor effect (KIR–
HLA mismatch, KIR–ligand missing)
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are expanded and activated in vitro prior to adoptive 
transfer using various cytokines (IL-2, IL-15 or IL-21) 
and growth factors [27–29]. In addition, monoclonal 
antibodies blocking inhibitory KIRs can be used to 
stimulate NK cell function [30, 31].
(3) Antibody-dependent cytotoxic cell lysis (ADCC) NK 
cells express the activating receptor type IIIA Fc recep-
tor (CD16). This receptor enables NK cells to recog-
nize antibodies on target cells, which triggers subse-
quently the destruction of the cells via ADCC. This 
effect can be augmented using monoclonal antibodies 
that stimulate endogenous or adoptive NK cells. Evi-
dence for NK cell-mediated ADCC has been given in 
clinical studies using antibody treatment of non-Hodg-
kin lymphoma with rituximab (anti-CD20) [32, 33], 
multiple myeloma with daratumumab in combination 
with all-trans retinoic acid [34] or human anti-KIR 
antibody IPH2102 and lenalido [31], metastatic breast 
cancer with herceptin (anti-trastuzumab) [35] and met-
astatic colorectal cancer or squamous cell carcinoma 
of the head and neck by the epidermal growth factor 
receptor (EGFR) inhibitor cetuximab [36].
(4) NK cell lines/chimeric antigen receptor modification 
There are seven established NK cells lines: NK-92, 
YT, NKL, HANK-1, KHYG-1, NK-YS and NKG [37, 
38]. These cell lines are ideal candidates for the expan-
sion under GMP conditions. However, only the human 
NK-92 cell line has shown to be safe and efficient in 
clinical trials [39–41]. Recently gene transfer of CARs 
into primary NK cells or NK-92 has brought new ther-
apeutic options [42, 43].
Stimulation of NK cell activity to enhance 
immunotherapy
It was discovered early on that exposure to stimulatory fac-
tors such as the cytokine IL-2 enhanced NK cell potency 
significantly. This property was already exploited clinically 
in the 1980s by investigators from the National Cancer 
Institute (NCI, USA) [44, 45]. However, clinical outcomes 
of these original studies did not match expectations. Early 
clinical trials aimed to ‘in vivo’ expand NK cells and to 
improve their antitumor activity by administrating systemic 
cytokines, such as IL-2, into the patients with poor clinical 
outcome due to high toxicity of IL-2. Similarly, low-dose 
IL-2 administration after autologous stem cell transplan-
tation with lower side effects showed reduced cytotoxic 
functionality.
In another approach, leukapheresis products were IL-
2-stimulated in vitro for a short term (overnight or a few 
days), to generate lymphokine-activated killer (LAK) cells 
for re-application to patients. However, such LAK cells 
were essential T cells with the effector NK cells substitut-
ing only a minor fraction. Short-term stimulation of leu-
kapheresis products was insufficient to achieve notable 
expansion and activation of the NK cells that represent 
only 10–20 % of peripheral blood lymphocytes. Alterna-
tively, high doses of IL-2 were directly administered to 
patients to activate NK cells in vivo. However, this clinical 
treatment modality was afflicted with serious side effects 
[46]. In addition, IL-2 leads to the stimulation of regula-
tory T cells; thus, NK cell ex vivo stimulation with other 
cytokines would be favorable [47, 48]. Recently, there are 
indications that brief pre-activation of NK cells with novel 
cytokines such as IL-12, IL-15 and IL-18 induces CD25 
(low-affinity IL-2 receptor alpha chain) expression on NK 
cells [49]. Thus, immunotherapy with cytokine-cocktail 
pre-activated NK cells may pose a novel treatment option 
in the near future. Significant technological advances, a 
better understanding of NK cell biology and the discovery 
of novel stimulatory factors paved the way for entirely new 
clinical study designs. Recently the field of NK cell therapy 
is rapidly internationally emerging and a variety of pioneer-
ing approaches is under development or in clinical testing 
extensively reviewed elsewhere [50, 51].
Selection and expansion of primary NK cells 
for clinical application
Several protocols have been established aiming to gener-
ate sufficient numbers and purity of NK cells by keeping 
their functional capabilities [27–29, 50]. However, only a 
few strategies have been developed which follow the strin-
gent requirements of GMP. Besides cellular efficacy of NK 
cell components, GMP-based manufacturing is essential 
for clinical application [28, 52, 53]. In general, NK cells 
can be expanded from PBMC, umbilical cord blood (CB) 
or bone marrow (BM) and hESC or iPS.
NK cells from peripheral blood mononuclear cells
NK cell is in PBMC with a range of 5–20 %. Therefore, 
various protocols have been used to isolate and preferen-
tially expand primary NK cells from PBMC [50]. The 
common principle is a combination of cell selection and 
depletion using immunomagnetic beads [52]. These pro-
tocols use leukapheresis products for the clinical-grade 
purification of NK cells by depleting CD3 cells followed 
by selection of CD56 cells [28] or in combination with 
subsequent short-term (14-day) expansion with IL-2 [52]. 
Clinical-grade expansion of NK cells in lymphokine-acti-
vated killer (LAK) cell cultures for 28 days with IL-15 
has been reported [27]. NK cell expansion requires multi-
ple signals for survival, proliferation and activation. Thus, 
481Cancer Immunol Immunother (2016) 65:477–484 
1 3
expansion strategies have been focused either to substitute 
these factors using autologous feeder cells and/or to use 
genetically modified allogeneic feeder cells Functional 
activity is defined by cytotoxicity against various malig-
nant cell lines and expression pattern of NK cell receptor 
(cluster of differentiation (CD)-16, natural killer group-2 
member D (NKG2D), CD69, NKp30, NKp44, NKp46 
and CD158b. Expansion of NK with autologous PBMC as 
feeder cells has been shown to generate functional active 
NK cells with a therapeutic cells dosage [54]. Using GMP-
compliant components and autologous feeder cells, purified 
NK cells were effectively expanded (2500-fold at day 17) 
[54]. Similarly, large-scale expansion of GMP-compliant 
NK cells with cytolytic activity against tumor cells has 
been reported using autologous PBMCs in the presence of 
OKT3 and IL-2 at 14 day [55]. Other feeder cells such as 
Jurkat T-lymphoblast subline KL-1 have been used which 
achieved expansion of NK cells accompanied by recipro-
cal inhibition of T-cell growth [56]. Promising results were 
also obtained by the leukemia cell line K562, genetically 
altered to express membrane-bound form of IL-15 and the 
4-1BB (CD137L), which has led to an 277-fold expan-
sion after 3 weeks (21 days) in culture [57]. More recently, 
K562 cell lines have been engineered to express membrane-
bound IL-21 along with CD137L [58]. Expansion was 
highly selectively for NK cells and reached 100-fold by 
3 weeks while CD3+ T cells went from initially 60–1 %. 
[59]. Genetically modified K562 feeder cells have also the 
benefit to be used as frozen stock (vials) [60]. In addition 
to the expansion of total NK cells, strategies for selective 
expansion of individual NK cell subpopulations have been 
developed. These strategies are based on the observation 
that despite a fixed number of inherited KIR genes, each 
individual NK cell expresses a different number of KIR 
genes on the cell surface [61]. NK cells with particular sets 
of inhibitory receptors have been named ‘single-KIR’ cells 
in the context of developing KIR mismatched cell compo-
nents for therapeutic use. ‘Single-KIR’ NK cells have been 
shown to lysis human acute myeloid leukemia (AML) cells 
in vitro and in vivo [62, 63]. Selection and expansion of 
clinical-grade single-KIR+ NK cell subsets have been 
established using a GMP-based approach [63].
NK cells from umbilical cord blood or bone 
marrow‑derived CD34+ cells
CD34+ hematopoietic progenitors from umbilical CB or 
BM are considered as an excellent source for cell thera-
peutic applications [64]. Earlier studies have been chal-
lenged to reach efficient numbers of NK cells considering 
the low number of NK cells in CB units. Therefore, dif-
ferent protocols have been developed for the generation 
of NK cells from CD34+ cells from BM and later from 
CB using co-culturing systems with stromal cell lines and 
a combination of cytokines that promote the development 
of NK cells [65–68]. Many culture systems contain in gen-
eral components of animal origin (e.g., bovine serum), and 
this will require changes to adapt them for clinical applica-
tions. More recently, a cell culture platform for the ex vivo 
expansion and NK differentiation from CB-derived CD34+ 
cells has been established. This method uses clinical-grade 
serum-free culture medium, no feeder cells and a mixture 
of heparin and cytokines as a substitute for the extracel-
lular microenvironment of BM in static cell culture bags 
and automated bioreactor [69]. Expansion of up to 10*10 
CD34+-derived NK cells NK cells was feasible with high 
levels of activating receptors (e.g., NKG2D and NCR) and 
the ability to efficiently lyse myeloid leukemia and mela-
noma cell lines, as well as primary leukemia blasts [70]. A 
phase I trial in elderly AML patients using NK cells based 
upon this expansion technique is in progress (CCMO no. 
NL31699 and Dutch Trial Register nr. 2818) [70].
NK cells from embryonic stem cells or induced 
pluripotent stem cells
The potential to use NK cell from hESC or iPS for immu-
notherapeutic applications has been reviewed recently by 
Francisco Borrego [71]. In contrast to research and clinical 
studies with NK cell from PBMC and or CD34+CB cells, 
the generation of NK cells form hESC or iPS is a relative 
new area with an sophisticated approach [72]. Currently, 
experimental design is focused to optimize the culture 
conditions to generate these cells. Efficient generation of 
functional NK cells from hESC has been described CD34+ 
with acquired functional receptors and cytolytic activ-
ity [73, 74]. In addition, these cells could lyse malignant 
cells by both direct cell-mediated cytotoxicity and ADCC. 
Clinical-scale generation of NK cells has been published 
by Kaufmann and co-workers [75]. This method allows the 
production of mature and functional NK cells from hESC 
and iPS after expansion for at least 2 month using IL-21 
expressing antigen-presenting cells. Harvested NK cell 
numbers are sufficient to be used for treatment of single 
patients.
Future perspectives
Current insights into the cellular mechanism geared by 
receptor–ligand interactions and structural analysis of 
receptor binding affinities will lead to develop more spe-
cific targeting strategies against malignant hematopoietic 
or solid tumor cells using NK cell-based therapies. Future 
studies will lead to a better understanding of the complex 
interactions between inhibitory and activating signaling 
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mechanisms including memory and education of NK cells. 
This should open a broad therapeutic field in using NK cells 
for either individualized or ‘off-the-shelf’ cell therapy. The 
promising results in overcoming the limited number of NK 
cells by expansion and the feasibility to use GMP-compliant 
techniques for selection and depletion should enable to tai-
lor NK cell immunotherapy for various malignant diseases. 
Recent development in the clinical use of gene modified NK 
cell lines (e.g., CAR) and the development of expansion 
protocols for the clinical use of NK cell from hESC or iPS 
are challenging improvements for NK cell-based immuno-
therapy. Transfer of these protocols to clinical-grade produc-
tion of NK cells necessitates adaptation of GMP conditions, 
and the development of freezing conditions to establish NK 
cell stocks will require some effort and, however, should 
enhance the therapeutic options of NK cells in clinical.
Acknowledgments This work was supported by the LOEWE 
Center for Cell and Gene Therapy Frankfurt funded by the Hessisches 
Ministerium für Wissenschaft und Kunst funding reference number: 
III L 4- 518/17.004.
Compliance with ethical standards 
Conflict of interest None of the authors has a conflict of interest to 
declare.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Luetke-Eversloh M, Killig M, Romagnani C (2013) Signatures 
of human NK cell development and terminal differentiation. 
Front Immunol 4:499
 2. Navarro F, Llano M, Bellon T, Colonna M, Geraghty DE, Lopez-
Botet M (1999) The ILT2(LIR1) and CD94/NKG2A NK cell 
receptors respectively recognize HLA-G1 and HLA-E molecules 
co-expressed on target cells. Eur J Immunol 29:277–283
 3. Moretta L, Pietra G, Montaldo E, Vacca P, Pende D, Falco M, 
Del Zotto G, Locatelli F, Moretta A, Mingari MC (2014) Human 
NK cells: from surface receptors to the therapy of leukemias and 
solid tumors. Front Immunol 5:87
 4. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, 
Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, 
Velardi A (2002) Effectiveness of donor natural killer cell allo-
reactivity in mismatched hematopoietic transplants. Science 
295:2097–2100
 5. Locatelli F, Pende D, Mingari MC, Bertaina A, Falco M, Moretta 
A, Moretta L (2013) Cellular and molecular basis of haploiden-
tical hematopoietic stem cell transplantation in the successful 
treatment of high-risk leukemias: role of alloreactive NK cells. 
Front Immunol 4:15
 6. Aversa F, Martelli MF, Velardi A (2012) Haploidentical 
hematopoietic stem cell transplantation with a megadose 
T-cell-depleted graft: harnessing natural and adaptive immunity. 
Semin Oncol 39:643–652
 7. Martelli MF, Di Ianni M, Ruggeri L, Pierini A, Falzetti F, Carotti 
A, Terenzi A, Reisner Y, Aversa F, Falini B, Velardi A (2014) 
“Designed” grafts for HLA-haploidentical stem cell transplanta-
tion. Blood 123:967–973
 8. Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun 
K, O’Reilly RJ, Horowitz MM, Dupont B (2005) Improved out-
come in HLA-identical sibling hematopoietic stem-cell trans-
plantation for acute myelogenous leukemia predicted by KIR 
and HLA genotypes. Blood 105(12):4878–4884
 9. Park S, Kim K, Jang JH, Kim SJ, Kim WS, Kang ES, Jung CW 
(2015) KIR alloreactivity based on the receptor-ligand model is 
associated with improved clinical outcomes of allogeneic hemat-
opoietic stem cell transplantation: result of single center prospec-
tive study. Hum Immunol 76(9):636–643
 10. Leung W, Iyengar R, Triplett B, Turner V, Behm FG, Hol-
laday MS, Houston J, Handgretinger R (2005) Comparison 
of killer Ig-like receptor genotyping and phenotyping for 
selection of allogeneic blood stem cell donors. J Immunol 
174(10):6540–6545
 11. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T et al 
(2010) Donor selection for natural killer cell receptor genes 
leads to superior survival after unrelated transplantation for acute 
myelogenous leukemia. Blood 116:2411–2419
 12. Venstrom JM, Dupont B, Hsu KC, Pittari G, Gooley TA, Chewn-
ing JH, Spellman S, Haagenson M, Gallagher MM, Malkki M, 
Petersdorf E (2014) Donor activating KIR2DS1 in leukemia. N 
Engl J Med 371(21):2042
 13. Pittari G, Liu XR, Selvakumar A, Zhao Z, Merino E, Huse M, 
Chewning JH, Hsu KC, Dupont B (2013) NK cell tolerance of 
self-specific activating receptor KIR2DS1 in individuals with 
cognate HLA-C2 ligand. J Immunol 190(9):4650–4660
 14. Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, 
Le CT et al (2009) Donors with group B KIR haplotypes improve 
relapse-free survival after unrelated hematopoietic cell transplan-
tation for acute myelogenous leukemia. Blood 113:726–732
 15. Oevermann L, Michaelis SU, Mezger M, Lang P, Toporski J, 
Bertaina A, Zecca M, Moretta L, Locatelli F, Handgretinger R 
(2014) KIR B haplotype donors confer a reduced risk for relapse 
after haploidentical transplantation in children with ALL. Blood 
124(17):2744–2747
 16. Venstrom JM, Gooley TA, Spellman S, Pring J, Malkki M, 
Dupont B et al (2010) Donor activating KIR3DS1 is associated 
with decreased acute GvHD in unrelated allogeneic hematopoi-
etic cell transplantation. Blood 115:3162–3165
 17. Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spell-
man S, Haagenson M, Gallagher MM, Malkki M, Petersdorf 
E, Dupont B, Hsu KC (2012) HLA-C-dependent prevention of 
leukemia relapse by donor activating KIR2DL1. N Engl J Med 
367:805–816
 18. Yawata M, Yawata N, Draghi M, Little AM, Partheniou F, Par-
ham P (2006) Roles for HLA and KIR polymorphisms in natural 
killer cell repertoire selection and modulation of effector func-
tion. J Exp Med 203:633–645
 19. Bari R, Rujkijyanont P, Sullivan E, Kang G, Turner V, Gan K, 
Leung W (2013) Effect of donor KIR2DL1 allelic polymorphism 
on the outcome of pediatric allogeneic hematopoietic stem-cell 
transplantation. J Clin Oncol 31(30):3782–3790
 20. Foley B, Cooley S, Verneris MR, Pitt M, Curtsinger J, Luo X, 
Lopez-Verges S, Lanier LL, Weisdorf D, Miller JS (2012) Cyto-
megalovirus reactivation after allogeneic transplantation pro-
motes a lasting increase in educated NKG2C+ natural killer 
cells with potent function. Blood 119:2665–2674
 21. Green ML, Leisenring WM, Xie H, Walter RB, Mielcarek M, 
Sandmaier BM, Riddell SR, Boeckh M (2013) CMV reactivation 
483Cancer Immunol Immunother (2016) 65:477–484 
1 3
after allogeneic HCT and relapse risk: evidence for early protec-
tion in acute myeloid leukemia. Blood 122:1316–1324
 22. Zambello R, Teramo A, Barila G, Gattazzo C, Semenzato G 
(2014) Activating KIRs in chronic lymphoproliferative disor-
der of NK cells: protection from viruses and disease induction? 
Front Immunol 5:72
 23. Burns LJ, Weisdorf DJ, DeFor TE, Vesole DH, Repka TL, Bla-
zar BR et al (2003) IL-2-based immunotherapy after autologous 
transplantation for lymphoma and breast cancer induces immune 
activation and cytokine release: a phase I/II trial. Bone Marrow 
Transplant 32:177–186
 24. Sakamoto N, Ishikawa T, Kokura S, Okayama T, Oka K, Ideno 
M, Sakai F, Kato A, Tanabe M, Enoki T, Mineno J, Naito Y, 
Itoh Y, Yoshikawa T (2015) Phase I clinical trial of autologous 
NK cell therapy using novel expansion method in patients with 
advanced digestive cancer. J Transl Med 13(1):277
 25. Miller JS, Soignier Y, Panoskaltsis-Mortari A et al (2005) Success-
ful adoptive transfer and in vivo expansion of human haploidenti-
cal NK cells in patients with cancer. Blood 105(8):3051–3057
 26. Ruggeri L, Mancusi A, Capanni M, Martelli MF, Velardi A 
(2011) Exploitation of alloreactive NK cells in adoptive immu-
notherapy of cancer. Curr Opin Immunol 17(2):211–217
 27. Suck G, Oei VY, Linn YC, Ho SH, Chu S, Choong A, Niam M, 
Koh MB (2011) Interleukin-15 supports generation of highly 
potent clinical-grade natural killer cells in long-term cultures for 
targeting hematological malignancies. Exp Hematol 39:904–914
 28. Brehm C, Huenecke S, Quaiser A, Esser R, Bremm M, Kloess 
S, Soerensen J, Kreyenberg H, Seidl C, Becker PS, Mühl H, 
Klingebiel T, Bader P, Passweg JR, Schwabe D, Koehl U (2011) 
IL-2 stimulated but not unstimulated NK cells induce selective 
disappearance of peripheral blood cells: concomitant results to a 
phase I/II study. PLoS One 6(11):e27351
 29. Suck G, Koh MB (2010) Emerging natural killer cell immuno-
therapies: large-scale ex vivo production of highly potent anti-
cancer effectors. Hematol Oncol Stem Cell Ther 3:135–142
 30. Binyamin L, Alpaugh RK, Hughes TL, Lutz CT, Campbell KS, 
Weiner LM (2008) Blocking NK cell inhibitory self-recognition 
promotes antibody-dependent cellular cytotoxicity in a model of 
anti-lymphoma therapy. J Immunol 180:6392–6401
 31. Nijhof IS, Lammerts van Bueren JJ, van Kessel B, Andre P, 
Morel Y, Lokhorst HM, van de Donk NW, Parren PW, Mutis 
T (2015) Daratumumab-mediated lysis of primary multiple 
myeloma cells is enhanced in combination with the human 
anti-KIR antibody IPH2102 and lenalidomide. Haematologica 
100(2):263–268
 32. Alderson KL, Sondel PM (2011) Clinical cancer therapy by 
NK cells via antibody-dependent cell-mediated cytotoxicity. J 
Biomed Biotechnol 2011:379123
 33. Du J, Lopez-Verges S, Pitcher BN, Johnson J, Jung SH, Zhou 
L, Hsu K, Czuczman MS, Cheson B, Kaplan L, Lanier LL, Ven-
strom JM (2014) CALGB 150905 (Alliance): rituximab broad-
ens the antilymphoma response by activating unlicensed NK 
cells. Cancer Immunol Res 2(9):878–889
 34. Nijhof IS, Groen RW, Lokhorst HM, van Kessel B, Bloem AC, 
van Velzen J, de Jong-Korlaar R, Yuan H, Noort WA, Klein 
SK, Martens AC, Doshi P, Sasser K, Mutis T, van de Donk NW 
(2015) Upregulation of CD38 expression on multiple myeloma 
cells by all-trans retinoic acid improves the efficacy of daratu-
mumab. Leukemia 29(10):2039–2049
 35. Daldrup-Link HE, Meier R, Rudelius M, Piontek G, Piert M, 
Metz S, Settles M, Uherek C, Wels W, Schlegel J, Rummeny EJ 
(2005) In vivo tracking of genetically engineered, anti-HER2/
neu directed natural killer cells to HER2/neu positive mammary 
tumors with magnetic resonance imaging. Eur Radiol 15(1):4–13
 36. Monteverde M, Milano G, Strola G, Maffi M, Lattanzio L, 
Vivenza D, Tonissi F, Merlano M, Lo Nigro C (2015) The 
relevance of ADCC for EGFR targeting: a review of the litera-
ture and a clinically-applicable method of assessment in patients. 
Crit Rev Oncol Hematol 95(2):179–190
 37. Suck G, Branch DR, Keating A (2006) Irradiated KHYG-1 
retains cytotoxicity: potential for adoptive immunotherapy with 
a natural killer cell line. Int J Radiat Biol 82(5):355–361
 38. Gong JH, Maki G, Klingemann HG (1994) Characteriza-
tion of a human cell line (NK-92) with phenotypical and func-
tional characteristics of activated natural killer cells. Leukemia 
8(4):652–658
 39. Tonn T, Becker S, Esser R, Schwabe D, Seifried E (2001) Cellu-
lar immunotherapy of malignancies using the clonal natural killer 
cell line NK-92. J Hematother Stem Cell Res 10(4):535–544
 40. Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl 
U, Suttorp M, Seifried E, Ottmann OG, Bug G (2013) Treatment 
of patients with advanced cancer with the natural killer cell line 
NK-92. Cytotherapy 15(12):1563–1570
 41. Arai S, Meagher R, Swearingen M et al (2008) Infusion of the 
allogeneic cell line NK-92 in patients with advanced renal cell 
cancer or melanoma: a phase I trial. Cytotherapy 10(6):625–632
 42. Boissel L, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, 
Wels WS, Klingemann H (2013) Retargeting NK-92 cells by 
means of CD19- and CD20-specific chimeric antigen receptors 
compares favorably with antibody-dependent cellular cytotoxic-
ity. Oncoimmunology 2(10):e26527
 43. Hermanson DL, Kaufman DS (2015) Utilizing chimeric anti-
gen receptors to direct natural killer cell activity. Front Immunol 
6:195
 44. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, 
Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT 
et al (1985) Observations on the systemic administration of 
autologous lymphokine-activated killer cells and recombinant 
interleukin-2 to patients with metastatic cancer. N Engl J Med 
313:1485–1492
 45. Rosenberg SA (1988) The development of new immunotherapies 
for the treatment of cancer using interleukin-2. A review. Ann 
Surg 208:121–135
 46. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan 
WM, Seipp CA, White DE (1989) Experience with the use of 
high-dose interleukin-2 in the treatment of 652 cancer patients. 
Ann Surg 210:474–484
 47. Knorr DA, Bachanova V, Verneris MR, Miller JS (2014) Clinical 
utility of natural killer cells in cancer therapy and transplanta-
tion. Semin Immunol 26(2):161–172
 48. Skrombolas D, Frelinger JG (2014) Challenges and developing 
solutions for increasing the benefits of IL-2 treatment in tumor 
therapy. Expert Rev Clin Immunol 10(2):207–217
 49. Leong JW, Chase JM, Romee R, Schneider SE, Sullivan RP, 
Cooper MA, Fehniger TA (2014) Preactivation with IL-12, 
IL-15, and IL-18 induces CD25 and a functional high-affinity 
IL-2 receptor on human cytokine-induced memory-like natural 
killer cells. Biol Blood Marrow Transplant 20:463–473
 50. Klingemann H (2015) Challenges of cancer therapy with natural 
killer cells. Cytotherapy 17(3):245–249
 51. Childs RW, Berg M (2013) Bringing natural killer cells to the 
clinic: ex vivo manipulation. Hematology/the Education Pro-
gram of the American Society of Hematology American Society 
of Hematology Education Program, pp 234–246
 52. Koehl U, Brehm C, Huenecke S, Zimmermann SY, Kloess S, 
Bremm M, Ullrich E, Soerensen J, Quaiser A, Erben S, Wunram 
C, Gardlowski T, Auth E, Tonn T, Seidl C, Meyer-Monard S, 
Stern M, Passweg J, Klingebiel T, Bader P, Schwabe D, Esser R 
(2013) Clinical grade purification and expansion of NK cell prod-
ucts for an optimized manufacturing protocol. Front Oncol 3:118
 53. Linn YC, Yong HX, Niam M, Lim TJ, Chu S, Choong A, Chuah 
C, Goh YT, Hwang W, Loh Y, Ng HJ, Suck G, Chan M, Koh 
484 Cancer Immunol Immunother (2016) 65:477–484
1 3
M (2012) A phase I/II clinical trial of autologous cytokine-
induced killer cells as adjuvant immunotherapy for acute and 
chronic myeloid leukemia in clinical remission. Cytotherapy 
14(7):851–859
 54. Ahn Yong-Oon, Kim Saerom, Kim Tae Min, Song Eun Young, 
Park Myoung Hee, Heo Dae Seog (2013) Irradiated and acti-
vated autologous PBMCs induce expansion of highly cytotoxic 
human NK cells in vitro. J Immunother 36:373–381
 55. Lim O, Lee Y, Chung H, Her JH, Kang SM, Jung MY, Min B, 
Shin H, Kim TM, Heo DS, Hwang YK, Shin EC (2013) GMP-
compliant, large-scale expanded allogeneic natural killer cells 
have potent cytolytic activity against cancer cells in vitro and 
in vivo. PLoS One 8(1):e53611
 56. Lim SA, Kim TJ, Lee JE, Sonn CH, Kim K, Kim J, Choi JG, 
Choi IK, Yun CO, Kim JH, Yee C, Kumar V, Lee KM (2013) Ex 
vivo expansion of highly cytotoxic human NK cells by coculti-
vation with irradiated tumor cells for adoptive immunotherapy. 
Cancer Res 73(8):2598–25607
 57. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, 
Eldridge P, Leung WH, Campana D (2009) Expansion of highly 
cytotoxic human natural killer cells for cancer cell therapy. Can-
cer Res 69(9):4010–4017
 58. Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp 
LM et al (2012) Membrane-bound IL-21 promotes sustained 
ex vivo proliferation of human natural killer cells. PLoS One 
7(1):e30264
 59. Wang X, Lee DA, Wang Y, Wang L, Yao Y, Lin Z, Cheng J, Zhu 
S (2013) Membrane-bound interleukin-21 and CD137 ligand 
induce functional human natural killer cells from peripheral 
blood mononuclear cells through STAT-3 activation. Clin Exp 
Immunol 172(1):104–112
 60. Baek HJ, Kim JS, Yoon M, Lee JJ, Shin MG, Ryang DW, Kook 
H, Kim SK, Cho D (2013) Ex vivo expansion of natural killer 
cells using cryopreserved irradiated feeder cells. Anticancer Res 
33(5):2011–2019
 61. Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Wei-
denbach K, Corliss B, Tyan D, Lanier LL, Parham P (1997) 
Human diversity in killer cell inhibitory receptor genes. Immu-
nity 7:753–763
 62. Langenkamp U, Siegler U, Jörger S, Diermayr S, Gratwohl A, 
Kalberer CP, Wodnar-Filipowicz A (2009) Human acute myeloid 
leukemia CD34+CD38- stem cells are susceptible to allorecog-
nition and lysis by single KIR-expressing natural killer cells. 
Haematologica 94(11):1590–1594
 63. Siegler U, Meyer-Monard S, Jörger S, Stern M, Tichelli A, Grat-
wohl A, Wodnar-Filipowicz A, Kalberer CP (2010) Good manu-
facturing practice-compliant cell sorting and large-scale expan-
sion of single KIR-positive alloreactive human natural killer 
cells for multiple infusions to leukemia patients. Cytotherapy 
12(6):750–763
 64. Schönberg K, Fischer JC, Kögler G, Uhrberg M (2011) Neona-
tal NK-cell repertoires are functionally, but not structurally, biased 
toward recognition of self HLA class I. Blood 117(19):5152–5156
 65. Fluevano M, Domogala A, Blundell M, Jackson N, Pedroza-
Pacheco I, Derniame S et al (2014) Frozen cord blood hemat-
opoietic stem cells differentiate into higher numbers of func-
tional natural killer cells in vitro that mobilized hematopoietic 
stem cells or freshly isolated cord blood hematopoietic stem 
cells. PLoS One 9:e87086
 66. Pinho MJ, Punze M, Sousa M, Barros A (2011) Ex vivo differ-
entiation of natural killer cells from human umbilical cord blood 
CD34+ progenitor cells. Cell Commun Adhes 18:45–55
 67. Frias AM, Porada CD, Crapnell KB, Cabral JM, Zanjani ED, 
Almeida-Porada G (2008) Generation of functional natural killer 
and dendritic cells in a human stromal- based serum-free cul-
ture system designed for cord blood expansion. Exp Hematol 
36:61–68
 68. Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, 
deWitte T et al (2011) Clinical-grade generation of active NK 
cells from cord blood hematopoietic progenitor cells for immu-
notherapy using a closed-system culture process. PLoS One 
6:e20740
 69. Spanholtz J, Tordoir M, Eissens D, Preijers F, van der Meer A, 
Joosten I et al (2010) High log-scale expansion of functional 
human natural killer cells from umbilical cord blood CD34-posi-
tive cells for adoptive cancer immunotherapy. PLoS One 5:e9221
 70. Chouaib S, Pittari G, Nanbakhsh A, El Ayoubi H, Amsellem S, 
Bourhis JH, Spanholtz J (2014) Improving the outcome of leu-
kemia by natural killer cell-based immunotherapeutic strategies. 
Front Immunol 5:95
 71. Eguizabal C, Zenarruzabeitia O, Monge J, Santos S, Angel 
Vesga Maruri N, Arrieta A, Rinon M, Tamayo-Orbegozo E, Amo 
L, Larrucea S, Borrego F (2014) Natural killer cells for cancer 
immunotherapy: pluripotent stem cells-derived NK cells as an 
immunotherapeutic perspective. Front, Immunol Article 439
 72. Woll PS, Grzywacz B, Tian X, Marcus RK, Knorr DA, Verneris 
MR et al (2009) Human embryonic stem cells differentiate into 
a homogeneous population of natural killer cells with potent 
in vivo antitumor activity. Blood 113:6094–6101
 73. Woll PS, Martin CH, Miller JS, Kaufman DS (2005) Human 
embryonic stem cell-derived NK cells acquire functional recep-
tors and cytolytic activity. J Immunol 175:5095–5103
 74. Knorr DA, Bock A, Brentjens RJ, Kaufman DS (2013) Engi-
neered human embryonic stem cell-derived lymphocytes to 
study in vivo trafficking and immunotherapy. Stem Cells Dev 
22:1861–1869
 75. Knorr DA, Ni Z, Hermanson D, Hexum MK, Bendzick L, 
Cooper LJ et al (2013) Clinical-scale derivation of natural killer 
cells from human pluripotent stem cells for cancer therapy. Stem 
Cells Transl Med 2:274–283
